More than 80% of children with ALL are now cured with chemotherapy without need for transplantation. This remarkable progress is the result of serial large-scale randomized clinical trials incorporating improvements in risk group assignment, administration of risk-adjusted therapy and intensified therapy for children with high-risk disease. Despite these advances, significant numbers of children still die of relapsed or refractory ALL, as ALL is the most frequent malignancy of childhood. This review focuses on the appropriate use of transplantation for children with ALL and optimization of transplant procedures to improve survival and reduce late consequences of therapy.
Introduction
Defining the appropriate use of hematopoietic cell transplantation (HCT) for children with ALL is a dynamic process, requiring constant and careful assessment of the likelihood of cure with chemotherapy to identify the subset of children for whom transplant offers a better treatment option. Improved chemotherapy treatments now offer reasonable probability of cure to children previously thought to require transplantation for survival. The role of HCT is also influenced by changes in transplantation, for example, the improved availability of unrelated marrow donors or cord blood units with expansion of national registries means that the majority of children with ALL will have a potential stem cell source if transplant is required. In addition, improved outcomes of unrelated donor transplants with better HLA typing, incorporation of HLA-C into matching algorithms and the use of cord blood units with large cell doses mean that outcomes equivalent to those seen with matched sibling donors can be achieved with unrelated donor stem cell sources, although late morbidity from GVHD may be increased.
The remarkable progress achieved in the use of chemotherapy in treatment of ALL is the result of series of large-scale clinical studies conducted by co-operative clinical trial groups. In contrast, the performance of randomized controlled trials to compare chemotherapy with HCT has proved challenging, due at least in part to a lack of agreement that equipoise exists between the two treatments on the part of physicians and parents. The lack of randomized trials has lead to considerable reliance on retrospective registry studies to identify optimum treatment strategies. In this review, we will discuss data available to assist the clinician in deciding which children with ALL should be transplanted, and the best approach for performing the transplant.
Transplant for ALL in first remission
Many case series of HCT for ALL in CR1 have been published over the years (Table 1) . Overall, the majority of studies show at least a moderate reduction in relapse rate with transplantation compared with chemotherapy, but with increased treatment-related mortality. Variability in the data from different studies reflects differences in the definitions used for high-risk ALL meriting transplantation in CR1. Many of the criteria used in the past to define high risk (for example, T-cell ALL and mediastinal mass, high white cell count, t(4;11)) are no longer associated with markedly inferior outcomes with modern chemotherapy and would not currently be considered an indication of HCT in CR1. In the US, Ph þ ALL, low hypodiploidy and the small number of cases with primary induction failure are the only sub-types of ALL considered sufficiently high risk to merit consideration of transplantation in CR1 using current Children's Oncology Group chemotherapy, and each of these indications is discussed below. 1 Infants with ALL provide particular challenges, commonly presenting with biologically adverse features, altered drug pharmacokinetics and vulnerability to infection. The role of transplant for infant ALL in CR1 is controversial, and is also discussed below.
Ph-positive ALL
The low frequency (o4% of cases of childhood ALL) of Ph þ ALL has limited the identification of risk factors and optimal therapy. To try to circumvent this limitation, Aricoè t al. 2 analyzed pooled data from 326 children and young adults treated for Ph þ ALL by 10 study groups. The analysis showed that HCT from a matched sibling donor was superior to other types of transplantation (68% surviving at 5 years compared with 39% for unrelated donor transplantation). Results for children treated with chemotherapy and no transplant varied significantly according to age and white cell count at presentation; survival at 5 years was 49% in children with a low white count and age less than 10 years at presentation, but only 20% in those with a white count greater than 100 000/mm 3 at presentation. 2 These data support the common clinical practice of offering HCT in first remission to children with Ph þ ALL and a matched sibling donor. However, for the majority of children without a matched sibling donor, there is less clear consensus on optimum management. Studies reporting outcome of unrelated donor HCT in these patients, so far show mixed results. [2] [3] [4] Some recent reports have shown encouraging results for the use of alternate donor transplant for Ph þ ALL in CR1, and recent registry studies indicate that survival with a well-matched unrelated donor or moderately mismatched cord blood unit can be equivalent to a sibling donor graft. [5] [6] [7] Continued investigation of the role of unrelated donor HCT in first remission for children with Ph-positive ALL is justified, although late morbidity from GVHD should be followed, as comparisons with the outcome of chemotherapy are made. More insight into prognostic factors will also allow better stratification of patients to help improve outcomes. On the basis of current available data, 2,5 unrelated donor transplant should certainly be considered for children with NCI high-risk characteristics. In contrast, children with NCI good-risk characteristics and no well-matched sibling or unrelated donor may achieve acceptable results with chemotherapy. 2 The tyrosine kinase inhibitor imatinib has been shown to have activity in childhood ALL, and current clinical trials are studying whether chemotherapy outcomes can be improved by including imatinib in intensive chemotherapy. 8 It remains important to follow these studies carefully however, as imatinib, or other newer tyrosine kinase inhibitors may improve survival with chemotherapy sufficiently to allow use of transplantation only in CR2. In addition to incorporation into chemotherapy regimens, investigators have shown that imatinib is well tolerated when given prophylactically post transplantation, although current follow-up is too short to determine whether outcomes are improved. 9 Hypodiploid ALL Children with severe hypodiploidy (o45 chromosomes) have poor outcomes (o40% survival) with chemotherapy. 10 Most recently, Nachman et al. 11 reported 139 patients with ALL and hypodiploidy (fewer than 45 chromosomes) collected from 10 different national ALL study groups and single institutions. In contrast to previous studies suggesting that near-haploid cases with 24-29 chromosomes have particularly poor outcome, this report found no difference in outcome between patients with 24-29, 33-39 or 40-43 chromosomes, with poor outcomes in all these cases. However, compared to patients with fewer than 44 chromosomes, patients with 44 chromosomes had a significantly better survival (69%) suggesting that this group may not merit HCT in first remission. Twenty-nine children with hypodiploid ALL transplanted in first or second remission with a matched sibling donor between 1990 and 2001 have been reported to the International Bone Marrow Transplant Registry. Three-year survival was 65% (95% confidence interval 45-80%), supporting the use of early HCT in this small subgroup (M Eapen, personal communication, 2002).
Primary induction failure
A small subset (o2%) of children with ALL fail to achieve remission after 28 days of induction chemotherapy, and if they do achieve remission, only 40% will survive, suggesting that early transplantation might be of benefit. 12 Unfortunately, only small case series are available to assess the efficacy of transplant in this setting. Satwani et al. 13 included seven children with ALL and primary induction failure in a co-operative group study of transplantation in CR1, and five of seven survived, supporting this approach. In earlier studies, survival in six of eight children, and in 10 of 18 patients in a study of children and adults was reported. 14, 15 In the absence of larger groups of patients, prognosis must be approached with caution, particularly as the intensity of initial chemotherapy has changed, and children with refractory disease after current regimens may be different from those treated in earlier eras. 
Transplantation in CR3
Relatively few children with ALL are transplanted in CR3, as most children with available well-matched donors will be transplanted in CR2. Borgmann et al. 16 proposed that children with later relapse might defer transplant in CR2, and only be transplanted if relapse occurred and a third remission was achieved. This proposal was based on review of 33 children transplanted in CR3 who had event-free survival of 48% at 6 years, compared with 49% in those transplanted in CR2. The authors estimated that 60% of children with late relapse treated with chemotherapy would have a further relapse, and of these 60% would achieve CR3 (reasonable estimates). Assuming that about half of those transplanted would survive, the overall survival for this approach would be 58% (40% who never relapse plus 18% (0.6 Â 0.6 Â 0.5) who relapse, achieve CR3 and are then cured by transplant). While these estimates are reasonable for children with late relapse, most centers are reluctant to defer transplant for those with early relapse and/or a well-matched donor due to the challenge of achieving CR3.
Prognostic factors predicting outcome of unrelated donor transplant for children with ALL in CR3 were analyzed in a series of 35 consecutive mostly T-depleted transplants performed in Bristol, UK.
17 Event-free survival was 35%, with high rates of relapse and treatment-related mortality. Lengths of CR1 and CR2 predicted outcome, with shorter survival in children with short remissions, and event-free survival was reduced in children whose first relapse was an isolated extramedullary relapse.
Minimal residual disease
Newer technologies are being developed to better assess response to therapy in childhood ALL, as early response is a powerful prognostic indicator. The detection of minimal residual disease (MRD) using immunophenotyping or molecular detection of residual cells is increasingly being applied to clinical trials of chemotherapy for ALL. 1, 18 Future improvements in outcome and applicability of HCT for childhood ALL may result from development of methodologies to identify in the earliest possible time children who are destined to relapse, allowing HCT in first remission when outcomes are superior. The detection of MRD in children receiving chemotherapy, either as a harbinger of relapse or as a measure of inadequate early response to therapy will allow early referral for HCT as intensification therapy. [19] [20] [21] [22] [23] It is important to know that the significance of MRD varies in different genetic subtypes of leukemia. For example, MRD is cleared more promptly in children with ALL and TEL-AML1 compared to children with favorable trisomies, both groups with an excellent long-term prognosis. 18 Recent studies have also shown association between gene-expression profiling of ALL blasts at diagnosis and distinct immunophenotypic/genetic subtypes of ALL, treatment outcomes and risk of relapse. [24] [25] [26] [27] Further validation of these and similar findings in future could allow immediate referral of children with ALL destined to relapse for HCT in first remission.
Similarly, in recent years, there is growing interest in the role of MRD as a predictive marker for relapse following allogeneic transplantation. Most studies have shown that MRD detection in pre-and/or post-HCT samples predict increased risk of relapse following HCT. [28] [29] [30] Different approaches have been suggested to help improve transplant outcomes using MRD detection to modify either pre or post transplant therapy, for example, additional cytoreductive therapy pre-transplant to reduce the malignant clone and render the patients MRD-negative, designing transplant protocols favoring development of GVHD to increase GVL effect, use of donor lymphocyte infusion (DLI), and so on. Some of these interventions are limited by the practicality of these approaches. For example, heavily pretreated patients have limited options for further chemotherapy prior to transplant, rapid withdrawal of immunosuppression and DLI are associated with the risk of life-threatening GVHD and have very limited efficacy, and treatment of GVHD further increases risk of lifethreatening infections. Thus, although it is possible to identify patients at risk of relapse with MRD detection, strategies to respond to that information are limited. Moreover, many questions remain unanswered; for example, should we use MRD-negative status to assign patients to non-transplant treatment options to prevent transplantrelated mortality and long-term toxicity? Efforts to assess the clinical significance of pre-transplant MRD in children with ALL are hampered by the lack of prospective studies in large cohorts of homogeneously treated patients.
Infant ALL Molecular rearrangements that involve the MLL gene occur in a high proportion of leukemias arising in infants less than 1 year of age, most frequently a t(4;11)(q21;q23) translocation. Prognosis in MLL-rearranged ALL in infants is very poor with current chemotherapy, with generally less than 20% 5-year event-free survival. [31] [32] [33] Because of the poor response to chemotherapy, infants with MLL-rearranged ALL are often considered as candidates for early transplantation. The Seattle group analyzed results of 40 infants who received an HCT between 1982 and 2003. 34 Three-year disease-free survival was 73% in 14 patients transplanted in CR1, suggesting early (in CR1) HCT might benefit these children, as reported by others. In contrast, Interfant-99 enrolled 482 infants with ALL from 22 countries between 1999 and 2005, 35 and reported that MLL gene rearrangement, very high white cell count (4300 Â 10 9 /l), age o6 months and a poor response to the prednisone prophase were independently associated with inferior outcomes. However, the 4-year disease-free survival did not differ significantly between high-risk patients treated with chemotherapy alone (37.4%) versus chemotherapy plus HCT (50.2%) when adjusted for time to transplantation (P ¼ 0.19). There is a clear need for further prospective studies to define the role of HCT in infants at high risk for treatment failure. Such studies will need to be multi-institutional and possibly multi-national, as infant leukemia is rare. Studies should include evaluation of the late consequences of therapy in survivors, as morbidity can be significant in young children.
Transplant for ALL in second remission
The majority of children with ALL are considered as candidates for transplantation only if they relapse despite receiving chemotherapy. The appropriate use of HCT or chemotherapy alone for children with relapsed ALL remains a controversial topic. A number of co-operative groups, including Children's Oncology Group have attempted to compare outcomes of transplant and chemotherapy in randomized studies and have been unsuccessful, largely due to lack of acceptance of randomization by either or both of physicians and parents. In the absence of randomized data, the best available comparison comes from registry analyses and case series, summarized in Table 2 . Eapen et al. 36 compared 188 patients enrolled in Pediatric Oncology Group chemotherapy trials and 186 children who received HLA-matched sibling transplants between 1991 and 1997. For children with early first relapse (o36 months from diagnosis), risk of a second relapse was significantly lower after transplant with a TBI regimen (relative risk, 0.49; 95% confidence interval, 0.33-0.71, Po0.001) than chemotherapy treatment, and leukemia-free survival was improved. In contrast, transplant in CR2 did not offer an advantage over chemotherapy for children with a late relapse (X36 months) (P ¼ 0.78).
The Italian Bone Marrow Transplant group reported on 57 children who received allogeneic transplant for ALL in CR2 and compared them to 230 patients who received chemotherapy following their relapse. 37 In agreement with the findings of the Center for International Blood and Marrow Transplant Research study, these authors demonstrated that patients who had an early first relapse (o30 months) had significantly longer disease-free survival following transplant than treatment with chemotherapy, but this advantage was lost in patients with a later relapse (430 months following diagnosis).
The German pediatric cooperative groups (BFM and COALL) reported 51 children with ALL in CR2, receiving matched sibling donor transplant. 38 Comparison of HCT results with outcomes in children treated with chemotherapy for a BM relapse showed that patients with an initial remission longer than 18 months had comparable survival, whether treated with chemotherapy or BMT. Patients with an early relapse (CR1 o18 months) or a relapse of T-ALL had a minimal chance of surviving following chemotherapy, and survival rates were significantly improved by allogeneic HCT.
These data indicate that HCT from a matched family donor is usually the best option for a child with early relapse of ALL. Data are currently insufficient to determine definitively whether similar benefit can be achieved with alternative donor HCT, although in may centers, results comparable to those seen with sibling donors can be achieved with an eight allele-matched unrelated donor, supporting such an approach. Similarly, good outcomes are reported with one or two antigen-mismatched cord blood grafts, and this approach is being widely used. Future analyses of outcomes of unrelated donor stem cell sources should include consideration of late morbidities, including GVHD that may be increased with use of unrelated donor stem cells, in addition to consideration of survival. The majority of studies indicate that children with later relapse (generally a CR1 of X36 months) can achieve similar survival with chemotherapy or with transplant from a sibling donor, so treatment options for these children should be discussed carefully with the family.
Selecting the optimal conditioning regimen
Early transplant studies used a conditioning regimen of CY/TBI, commonly regarded as a standard approach to Table 2 BMT for children with ALL in second CR 39 The 3-year probability of leukemia-free survival was significantly higher in the group receiving CY/ TBI compared to the group receiving BU and CY. The risk of relapse was similar in the two groups, but treatmentrelated mortality was higher in children receiving BU and CY. Bunin et al. 40 reported similar inferior outcomes of a BU and CY conditioning compared with CY/TBI, in a small but prospective trial conducted by the Pediatric Blood and Marrow Transplant Consortium.
A recent large Center for International Blood and Marrow Transplant Research study compared 298 patients with ALL in CR1 or CR2 receiving HLA-matched sibling allografts after CY/TBI with 204 patients receiving VP-16/ TBI. 41 Four groups were compared: CY/TBI o13 Gy, CY/ TBI X13 Gy, VP-16/TBI o13 Gy and VP-16/TBI X13 Gy. In CR2, important differences in outcome among conditioning groups were identified. Relapse, treatment failure and mortality were reduced in recipients of VP-16 (regardless of TBI dose) or with TBI doses of X13 Gy in patients receiving CY. A striking reduction in relapse risk was observed in patients receiving X13 Gy TBI with CY when compared to CY/TBI using o13 Gy of radiation (P ¼ 0.0016). These data are further evidence for the importance of the conditioning regimen in disease control in transplantation for ALL.
Umbilical cord blood transplant for ALL
The establishment of banks of cryopreserved umbilical cord blood (UCB) for use in transplantation has been an important development in the treatment of children with ALL. Potential advantages of UCB include immediate availability of stored units (particularly valuable for patients in whom remissions are likely to be short) and reduced GVHD, a major reason for treatment failure in recipients of unrelated donor marrow. In a report from Minnesota, the median time needed to identify a suitably matched UCB graft was 13.5 days compared to 49 days for a compatible unrelated marrow donor. 42 Eapen et al. 7 compared outcome of 503 children with acute leukemia transplanted using UCB with 282 marrow recipients between 1995 and 2003. Four hundred and ninety-five patients with ALL were included, 186 in the marrow group and 309 in the UCB group. In comparison with allele-matched bone-marrow transplants, 5-year leukemia-free survival was similar after transplantation of UCB mismatched for either one or two antigens and possibly higher after transplants of HLA-matched UCB. Treatment-related mortality rates were higher after transplantation of two-antigen HLA-mismatched UCB (relative risk 2.31, P ¼ 0.0003) and possibly after one-antigen HLA-mismatched low-cell-dose (p0.3 Â 10 8 /kg) UCB transplants (relative risk 1.88, P ¼ 0.0455). Relapse rates were lower after two-antigen HLA-mismatched UCB transplants (54%, P ¼ 0.0045). These data support the use of HLAmatched and one-or two-antigen HLA-mismatched UCB with units of adequate size in children with acute leukemia who need transplantation.
Conclusion
It is essential to understand outcomes of chemotherapy for ALL to appropriately use HCT in children with ALL. Continuing review and re-evaluation of chemotherapy outcomes, stem cell sources and transplant outcomes is necessary as all these variables are constantly changing, requiring vigilance on the part of transplant physicians. Relapse remains the major reason for treatment failure, and current data illustrate the importance of radiation in the conditioning regimen for disease control. The use of MRD to predict outcome has the potential to identify patients who do or do not need transplant. Novel GVHD prophylaxis agents such as sirolimus, currently under investigation in a randomized study in the US in the Children's Oncology Group, might improve disease control.
